1. Home
  2. CRF vs CRVS Comparison

CRF vs CRVS Comparison

Compare CRF & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cornerstone Total Return Fund Inc. (The)

CRF

Cornerstone Total Return Fund Inc. (The)

HOLD

Current Price

$7.35

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$14.86

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRF
CRVS
Founded
N/A
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
1997
2016

Fundamental Metrics

Financial Performance
Metric
CRF
CRVS
Price
$7.35
$14.86
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$30.17
AVG Volume (30 Days)
924.5K
1.2M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
48.04
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.56
$3.38
52 Week High
$8.25
$26.95

Technical Indicators

Market Signals
Indicator
CRF
CRVS
Relative Strength Index (RSI) 58.31 45.36
Support Level $7.08 $13.81
Resistance Level $7.39 $19.21
Average True Range (ATR) 0.08 1.23
MACD 0.02 -0.08
Stochastic Oscillator 82.81 12.34

Price Performance

Historical Comparison
CRF
CRVS

About CRF Cornerstone Total Return Fund Inc. (The)

Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology, Health Care, Financials, Communication Services, Consumer Discretionary, Industrials, Exchange-Traded Funds, Utilities, Energy, Real Estate, and others.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: